STEVEN PRESTRELSKI - 31 Jan 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Scientific Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
01 Feb 2023, 15:12:37 UTC
Previous filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +150,000 +26% $0.000000 719,780 31 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.